O6-Benzylguanine and its role in chemotherapy

Clinical Cancer Research

Volumn 3, Issue 6, 1997, Pages 837-847

  Dolan, M Eileen ^a   Pegg, Anthony E ^b  

^a UNIVERSITY OF CHICAGO   (United States)

^b PENN STATE COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

6 O ALKYLGUANINE DNA ALKYLTRANSFERASE; 6 O BENZYLGUANINE; CARMUSTINE; CHLOROZOTOCIN; CISPLATIN; MELPHALAN; MESYLMESYLIC ACID 2 CHLOROETHYL ESTER; NITROSOUREA DERIVATIVE; STREPTOZOCIN; ANTINEOPLASTIC AGENT; DRUG DERIVATIVE; ENZYME INHIBITOR; GUANINE; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; O(6) BENZYLGUANINE; O(6)-BENZYLGUANINE;

CANCER CHEMOTHERAPY; CLINICAL TRIAL; DRUG RESISTANCE; HUMAN; NONHUMAN; PHASE 1 CLINICAL TRIAL; PREVENTION; PRIORITY JOURNAL; REVIEW; ANIMAL; DNA REPAIR; DRUG ANTAGONISM; NEOPLASM; XENOGRAFT;

ANIMALS; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARMUSTINE; DNA REPAIR; ENZYME INHIBITORS; GUANINE; HUMANS; NEOPLASMS; O(6)-METHYLGUANINE-DNA METHYLTRANSFERASE; TRANSPLANTATION, HETEROLOGOUS;

EID: 0030608633     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (126)

1. McCormick, J. E., and McElhinney, R. S. Nitrosoureas from chemist to physician: classification and recent approaches to drug design. Eur. J. Cancer, 26: 207-221, 1990.
2. Berger, N. A. Alkylating agents. In: V. T. DeVita, S. Hellman, and S. A. Rosenberg, Cancer: Principles and Practice of Oncology, Vol. I, pp. 400-409. Philadelphia: J. B. Lippincott Company, 1993.
3. Armitage, J. O., and Antman, K. H. High-Dose Cancer Therapy: Pharmacology, Hematopoietins, Stem Cells. Baltimore: Williams and Wilkins, pp. 385-401, 1995.
4. Deutsch, J., Green, S. B., Strike, T. A., Burger, P. C., Robertson, J. T., Selker, R. G., Shapiro, W. R., Mealey, J. Jr., Ransohoff, J., and Paoletti, P. Results of a randomized trial comparing BCNU plus radiotherapy, streptozotocin plus radiotherapy, BCNU plus hyperfractioned radiotherapy in the postoperative treatment of malignant glioma. Int. J. Radiat. Oncol. Biol. Phys., 16: 1389-1396, 1989.
5. Mahaley, M. S. Neuro-oncology index and review (adult primary brain tumors). J. Neuro-oncol., 11: 85-147, 1991.
6. Shapiro, W. R., Green, S. B., Burger, P. C., Mahaley, M. S., Jr., Selker, R. G., VanGilder, J. C., Robertson, J. T., Ransohoff, J., Mealey, J., Jr., and Strike, T. A. Randomized trial of three chemotherapy regimens and two radiotherapy regimens in postoperative treatment of malignant glioma. Brain Tumor Cooperative Group Trial 8001. J. Neurosurg., 71: 1-9, 1989.
7. Takakura, K., Abe, H., Tanaka, R., Kitamura, K., Miwa, T., Takeuchi, K., Yamamoto, S., Kageyama, N., Handa, H., and Mogaini, H. Effects of ACNU and radiotherapy on malignant glioma. J. Neurosurg., 64: 53-57, 1986.
8. Walker, M. D., Green, S. O., Bvar, D. P., Alexendar, E., Jr., Batzdorf, U., Brooks, W., Hunt, W., MacCarty, C. Mahaley, M. S., Mealey, J., Jr., Owens, G., Ransohoff, J., II, Robertson, J. T., Shapiro, W., Smith, K., Wilson, C. B., and Strike, T. A. Randomized comparisons of radiotherapy and nitrosoureas for the treatment of malignant gliomas after surgery. N. Engl. J. Med., 303: 1323-1329, 1980.
9. Coates, A. S. Systemic chemotherapy for malignant melanoma. World J. Surg., 16: 277-281, 1992.
10. Costanza, M. E., Nathanson, L., Schoenfeld, D., Wolter, J., Colsky, J., Regelson, W., Cunningham, T., and Sedransk, N. Results with methyl-CCNU and DTIC in metastatic melanoma. Cancer (Phila.), 40: 1010-1015, 1977.
11. Jacquillat, C. L., Khayat, D., Banzet, P., Weil, M., Fumoleau, D., Avril, M. F., Namer, M., Bonneterre, J., Kerbrat, P., Bonerandi, J. J., Bugat, R., Montcuquet, P., Cupissol, D., Lauvin, R., Vilmer, C. and Bizzari, J. P. Final report of the Phase II study of the nitrosourea fotemustine (S 1036) in 153 patients with disseminated malignant melanoma including brain metastases. Proc. Am. Assoc. Cancer Res., 30: 273, 1989.
12. Khayat, D., Bizzari, J. P., Frenay, M., Naman, H., Weil, M., Goupil, A., Namer, M., Rouesse, J., Banzet, P., and Jacquillat, C. Interim report of phase 11 study of new nitrosourea S 10036 in disseminated malignant melanoma. J. Natl. Cancer Inst., 80: 1407-1408, 1988.
13. Khayat, D., Cour, V., and Cohen-Aloro, G. Hepatic intra-arterial fotemustine for liver tumors: results of a multicentric phase II study on 49 patients. Proc. Am. Soc. Clin. Oncol., 8: 83, 1989.
14. Avril, M. F., Bonneterre, J., Delaunay, M., Grosshans, E., Fumoleau, P., Israel, L., Bugat, R., Namer, M., Cupissol, D., and Kerbrat, P. Combination chemotherapy of dacarbazine and fotemustine in disseminated malignant melanoma. Cancer Chemother. Pharmacol., 27: 81-84, 1990.
15. Fuller, L. M., and Hagemeister, F. B. Diagnosis and management of Hodgkin's disease in the adult. Cancer (Phila.), 51: 2469-2476, 1983.
16. Kelsen, D., Hudis, C., Niedzwiecki, D., Dougherty, J., Casper, E., Botet, J., Vinciguerra, V., and Rosenbluth, R. A phase III comparison trial of streptozotocin, mitomycin, and 5-fluorouracil with cisplatin, 1-β-D-arabinofuranosylcytosine, and caffeine in patients with advanced pancreatic carcinoma. Cancer (Phila.), 68: 965-969, 1991.
17. Weiss, R. B. Streptozotocin: a review of its pharmacology, efficacy and toxicity. Cancer Treat. Rep., 66: 427-438, 1982.
18. Woll, P. J., Crowtherl D., Johnson, P. W. M., Soukop, M., Harper, P. G., Harris, M., Brampton, M. H., and Newlands, E. S. Phase II trial of temozolomide in low-grade non-Hodgkin's lymphoma. Br. J. Cancer, 72: 183-184, 1995.
19. Bleehen, N. M., Newlands, E. S., Lee, S. M., Thatcher, N., Selby, P., Calvert, A. H., Rustin, G. J., Brampton, M., and Stevens, M. F. Cancer Research Campaign phase II trial of temozolomide in metastatic melanoma. J. Clin. Oncol., 13: 910-913, 1995.
20. Newlands, E. S., Blackledge, G. P., Slack, J. A., Rustin, G. J. S., Smith, D. B., Stuart, N. S. A., Quarterman, C. P., Hoffman, R., Stevens, M. F. G., Brampton, M. H., and Gibson, A. C. Phase I trial of temozolomide (CCRG 81045: M&B 39831: NSC 362856). Br. J. Cancer. 65: 287-291, 1992.
21. O'Reilly, S. M., Newlands, E. S., Glaser, M. G., Brampton, M., Rice, Edwards, J. M., Illingworth, R. D., Richards, P. G., Kennard, C., Colquhoun, I. R., and Lewis, P. Temozolomide: a new oral cytotoxic chemotherapeutic agent with promising activity against primary brain tumours. Eur. J. Cancer, 29A: 940-942, 1993.
22. Woolley, P. V., and Tew, K. D. Mechanisms of Drug Resistance in Neoplastic Cells, pp. 1-390. San Diego: Academic Press, 1988.
23. Bungo, M., Fujiwara, Y., Kasahara, K., Nakagawa, K., Ohe, Y., Sasaki, Y., Irino, S., and Saijo, N. Decreased accumulation as a mechanism of resistance to cis-diamminedichloroplatinum(II) in human non-small cell lung cancer cell lines: relation to DNA damage and repair. Cancer Res., 50: 2549-2556, 1990.
24. Waxman, D. Glulathione-S-transferases: role in alkylating agent resistance and possible target for modulation chemotherapy. Cancer Res., 50: 6449-6457, 1990.
25. Schector, R. L., Alaoui-Jamali, M. A., and Batist, G. Glutathione S-transferase in chemotherapy resistance and in carcinogenesis. Biochem. Cell Biol., 70: 349-353, 1992.
26. Campling, B. G., Baer, K., Baker, H. M., Lam, Y. M., and Cole, S. P. Do glutathione and related enzymes play a role in drug resistance in small cell lung cancer cell lines? Br. J. Cancer, 68: 327-335, 1993.
27. 6-alkylguanine-DNA alkyltransferase: regulation and importance in response to alkylating carcinogenic and therapeutic agents. Cancer Res., 50: 6119-6129, 1990.
28. Ali-Osman, F., Caughlan, J., and Gray, G. S. Decreased DNA interstrand cross-linking and cytotoxicity induced in human brain tumor cells by 1,3-bis(2-chloroethyl)-1-nitrosourea after in vivo reaction with glutathione. Cancer Res., 49: 5954-5958, 1989.
29. Ali-Osman, F. Quenching of DNA cross-link precursors of chloroethylnitrosoureas and attenuation of DNA interstrand cross-linking by glutathione. Cancer Res., 49: 5258-5261, 1989.
30. Smith, M. T., Evans, C. G., Doane-Setzer, P., Castro, V. M., Tahir, M. K., and Mannervik, B. Denitrosation of 1,3-bis(2-chloroethyl)-1-nitrosourea by class mu glutathione transferases and its role in cellular resistance in rat brain tumor cells. Cancer Res., 49: 2621-2625, 1989.
31. Berhane, K., Hao, X-Y., Egyhazi, S., Hansson, J., Ringborg, U., and Mannervik, B. Contribution of glutathione transferase M3-3 to 1,3-bis(2-chloroethyl)-1-nitrosourea resistance in a human non-small cell lung cancer cell line. Cancer Res., 53: 4257-4261, 1993.
32. Colinas, R. J., Hung, D. H., Walsh, A. C., and Lawrence, D. A. Hydroquinone resistance in a murine myeloblastic leukemia cell line: involvement of quinone reductase and glutathione-dependent detoxification in nonclassical multidrug resistance. Biochem. Pharmacol., 52: 945-956, 1996.
33. 6-alkylguanine-DNA alkyltransferase and glutathione to modulate nitrosourea resistance in breast cancer. Biochem. Pharmacol., 48: 543-548, 1994.
34. Friedman, H. S., Dolan, M. E., Kaufmann, S. H., Colvin, O. M., Griffith, O. W., Moschel, R. C., Schold, S. C., Bigner, D. D., and Ali-Osman, F. Elevated DNA polymerase-α. DNA polymerase-β, and DNA topoisomerase II in a melphalan-resistant rhabdomyosarcoma xenograft that is cross-resistant to nitrosoureas and topotecan. Cancer Res., 54: 3487-3493, 1994.
35. 6-alkylguanine. FASEB J., 6: 2302-2310, 1992.
36. 6-alkylguanine-DNA alkyltransferase. Prog. Nucleic Acid Res. Mol. Biol., 51: 167-223, 1995.
37. 6-methylguanine-DNA methyltransferase in cell survival, mutagenesis and carcinogenesis. Mutat. Res., 145: 1-16, 1985.
38. Mitra, S., and Kaina, B. Regulation of repair of alkylation damage in mammalian genomes. Prog. Nucleic Acid Res. Mol. Biol., 44: 109-142, 1993.
39. Ludlum, D. B. DNA alkylation by the haloethylnitrosoureas: nature of modifications produced and their enzymatic repair or removal. Mutat. Res., 233: 117-126, 1990.
40. Belanich, M., Pastor, M., Randall, T., Guerra, D., Kibitel, J., Alas, L., Li, B, Citron, M., Wasserman, P., White, A., Eyre, H., Jaeckle, K., Shulman, S., Rector, D., Prados, M., Coons, S., Shapiro, W., and Yarosh, D. B. Retrospective study of the correlation between the DNA repair protein alkyltransferase and survival of brain tumor patients treated with carmustine. Cancer Res., 56: 783-788, 1996.
41. 6-Alkylguanine-DNA alkyltransferase activity of human malignant glioma and its clinical implications. J. Neuro-oncol., 21: 135-140, 1994.
42. 6-Alkylguanine-DNA alkyltransferase and sensitivity to procarbazine in human brain tumor xenografts. J. Neurosurg., 70: 573-577, 1989.
43. 1-deoxyguanosinyl]-ethane, in DNA treated with N,N′-bis(2-chloroethyl-N-nitrosourea (BCNU). Cancer Res., 42: 3102-3105, 1982.
44. Kohn, K. W. Interstrand cross-linking of DNA by 1,3-bis(2-chloroethy)-1-nitrosourea and other 1-(2-haloethyl)-1-nitrosoureas. Cancer Res., 37: 1450-1454, 1977.
45. 6-alkylguanine-DNA alkyltransferase from human leukemic cells. Prevention of chloroethylnitrosourea-induced cross-links by purified enzyme. Pharmacol. Ther., 31: 121-140, 1985.
46. 6-alkylguanine-DNA alkyltransferase and BCNU-treated defined length synthetic oligodeoxynucleotides. Nucleic Acids Res., 16: 6779-6788, 1988.
47. 6-methylguanine-DNA methyltransferase and chloroethyl-nitrosourea-treated DNA. Cancer Res., 52: 6052-6058, 1992.
48. Zlotogorski, C., and Erickson, L. C. Pretreatment of normal human fibroblasts and human colon carcinoma cells with MNNG allows chloroethylnitrosourea to produce DNA interstrand crosslinks not observed in cells treated with chloroethylnitrosourea alone. Carcinogenesis (Lond.), 4: 759-763, 1983.
49. Futscher, B. W., Micetich, K. C., Barnes, D. M., Fisher, R. I., and Erickson, L. C. Inhibition of a specific DNA repair system and nitrosourea cytotoxicity in resistant human cancer cells. Cancer Commun., 1: 65-73, 1989.
50. 6-alkylguanine-DNA alkyltransferase in vivo by pretreatment with antineoplastic agents. Biochem. Pharmacol., 38: 929-934, 1989.
51. 6-methylguanine DNA methyltransferase activity and mRNA levels in HT-29 cells in vitro. Cancer Res., 51: 1581-1585, 1991.
52. Zeller, W. J., Berger, M. R., Henne, T., and Weber, E. More than additive toxicity of the combination of 1-methyl-1-nitrosourea plus 1,3-bis(2-chloroethyl)-1-nitrosourea in the rat. Cancer Res., 46: 1714-1716, 1986.
53. 6-alkylguanine-DNA alkyltransferase by streptozotocin in vivo. Cancer Res., 49: 3134-3138, 1989.
54. 6-alkylguanine-DNA transferase activity and sensitivity of human tumor cells and xenografts to 1,3-bis(2-chloroethyl)-1-nitrosourea. Cancer Chemother. Pharmacol., 32: 59-63, 1993.
55. 6-benzylguanine (BG). streptozotocin (STZ), and 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU) in vitro and in vivo. Biochem. Pharmacol., 48: 2127-2134, 1994.
56. 6-Alkylguanine-DNA alkyltransferase depletion and regeneration in human peripheral lymphocytes following dacarbazine and fotemustine. Cancer Res., 51: 619-623, 1991.
57. Micetich, K. C., Futscher, B., Koch, D., Fisher, R. I., and Erickson, L. C. Phase 1 study of streptozotocin-and carmustine-sequenced administration in patients with advanced cancer. J. Natl. Cancer Inst., 84: 256-260, 1992.
58. 6-alkylguanine-DNA alkyltransferase-mediated carmustine resistance using streptozotocin: a Phase I trial. Cancer Res., 52: 2456-2459, 1992.
59. Mitchell, R. B., Dolan, M. E. Janisch, L., Vogelzang, N. J., Ratain, M. J., and Schilsky, R. L. Sequential therapy with dacarbazine and carmustine: a phase I study. Cancer Chemother. Pharmacol., 34: 509-514, 1994.
60. Smith, D. C., Gerson, S. L., Liu, L., Donelly, S., Day, R., Trump, D. L., and Kirkwood, J. M. Carmustine and streptozotocin in refractory melanoma: an attempt at modulation of 6-alkylguanine alkyltransferase. Clin. Cancer Res., 2: 1129-1134, 1996.
61. 6-alkylguanine alkyltransferase-directed DNA repair in metastatic colon cancers. J. Clin. Oncol., 13: 2301-2308, 1995.
62. Gerard, B, Aamdal, S. Lee, S. M., Leyvraz, S., Lucas, C. D'Incalci, M., and Bizzari, J. P. Activity and unexpected lung toxicity of the sequential administration of two alkylating agents-dacarbazine and fotemustine-in patients with melanoma. Eur. J. Cancer, 29A: 711-719, 1993.
63. Saffhill, R., Margison, G. P., and O'Connor, P. J. Mechanism of carcinogenesis induced by alkylating agents. Biochem. Biophys. Acta, 823: 111-145, 1985.
64. 6-alkylguanines. Cancer Res., 45: 6413-6417, 1985.
65. 6-alkylguanine pretreatment on the sensitivity of human colon tumor cells to the cytotoxic effects of chloroethylating agents. Cancer Res., 46: 4500-4504, 1986.
66. Karran, P. Possible depletion of a DNA repair enzyme in human lymphoma cells by subversive repair. Proc. Natl. Acad. Sci. USA, 82: 5285-5289, 1985.
67. 6-methylguanine. Cancer Chemother. Pharmacol., 25: 103-108, 1989.
68. 6-benzylguanine with or without streptozotocin treatment enhances 1,3-bis(2-chloroethyl)-1-nitrosourea sensitivity in vitro. Cancer Res., 53: 4281-4286, 1993.
69. 6-benzylguanine combined with streptozotocin treatment enhances 1,3-bis(2-chloroethyl)-1-nitrosourea cytotoxicity. Cancer Res., 54: 4371-4375, 1994.
70. 6-benzylguanine provides a means to evaluate the role of this protein in protection against carcinogenic and therapeutic alkylating agents. Proc. Natl. Acad. Sci. USA, 87: 5368-5372, 1990.
71. 6-methylguanine. Carcinogenesis (Lond.), 12: 2305-2309, 1991.
72. 6-benzylguanine. Biochemistry, 32: 11998-12006, 1993.
73. 6-benzylguanine or N-methyl-N′-nitro-N-nitrosoguanidine. Carcinogenesis (Lond.), 12: 1679-1683, 1991.
74. 6-methylguanine-DNA methyltransferase and its possible application for monitoring human exposure to alkylating carcinogens. Cancer Res., 54: 3726-3731, 1994.
75. 6-methylguanine-DNA methyltransferase upon alkylation of its active site by SN1 (indirect-acting) and SN2 (direct acting) alkylating agents: breaking a "saltlink"? Biochemistry, 35: 12259-12266, 1996.
76. 6-benzylguanine or 1,3-bis(2-chloroethyl)-1-nitrosourea. Biochemistry, 35: 1328-1334, 1996.
77. 6-benzylguanine analogs on sensitivity of human tumor cells to the cytotoxic effects of alkylating agents. Cancer Res., 51: 3367-3372, 1991.
78. 6-alkylguanine-DNA alkyltransferase. J. Cancer Res. Clin. Oncol., 121: 225-229, 1995.
79. 6-alkylguanine-DNA transferase correlates with potentiation of temozolomide and CCNU toxicity in human tumor cells. Br. J. Cancer, 67: 1299-1302, 1993.
80. 6-benzylguanine in the enhancement of chloroethylnitrosourea cytotoxicity on brain tumours. Acta Neurochir., 128: 13-20, 1994.
81. 6-benzylguanine and sensitization to BCNU. Cancer Chemother. Pharmacol., 35: 262-266, 1995.
82. 6-benzylguanine and hypoxia on the cytotoxicity of 1,3-bis(2-chloroethyl)-1-nitrosourea in nitrosourea-resistant SF-763 cells. Cancer Chemother. Pharmacol., 32: 477-481, 1993.
83. 6-benzylguanine and its effect on sensitivity of a human glioma tumor to 1-(2-chloroethyl)-3-(4-methylcyclohexyl)-1-nitrosourea. Cancer Commun., 2: 371-377, 1990.
84. 6-benzylguanine on the sensitivity of human tumor xenografts to 1,3-bis(2-chloroethyl)-1-nitrosourea and on DNA interstrand cross-link formation. Cancer Res., 52: 1171-1175, 1992.
85. Friedman, H. S., Dolan, M. E., Moschel, R. C., Pegg, A. E., Felker, G. M., Rich, J., Bigner, D. D, and Schold, S. C., Jr. Enhancement of nitrosourea activity in medulloblastoma and glioblastoma multiforme. J. Natl. Cancer Inst., 84: 1926-1931, 1992.
86. 6-benzylguanine and 1,3-bis(2-chloroethyl)-1-nitrosourea. Cancer Chem. Pharmacol., 32: 471-476, 1993.
87. 6-benzylguanine analogs on the sensitivity of human colon tumor xenografts to BCNU. Biochem. Pharmacol., 46: 285-290, 1993.
88. 6-benzylguanine and 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU) in a human colon cancer xenograft completely resistant to BCNU alone. Biochem. Pharmacol., 45: 483-491, 1993.
89. 6-benzylguanine on the response to 1,3-bis(2-chloroethyl)-1 -nitrosourea in the Dunning R3327G model of prostatic cancer. Cancer Chemother. Pharmacol., 32: 221-225, 1993.
90. 6-benzylguanine increases the sensitivity of human primary bone marrow cells to the cytotoxic effects of temozolomide. Exp. Hematol., 23: 112-116, 1995.
91. 6-benzylguanine and its effectiveness against human brain tumor xenografts when administered in polyethylene glycol or cremophor-EL. Cancer Chemother. Pharmacol., 35: 121-126, 1994.
92. 6-benzylguanine (NSC-637037) and 1,3-bis(2-ehloroethyl)-1-nitrosourea (NSC 409962) in mice. Proc. Am. Assoc. Cancer Res., 35: 1954, 1994.
93. 6-benzylguanine (NSC-637037) and BCNU (carmustine. NSC-409962) in male and female Beagle dogs. Proc. Am. Assoc. Cancer Res., 35: 1952, 1994.
94. 6-alkylguanine-DNA alkyltransferase. Cancer Res., 54: 5123-5130, 1994.
95. 6-methylguanine-DNA methyltransferase inhibition in the nonhuman primate. Cancer Res., 55: 4606-4610, 1995.
96. 6-benzylguanine in rats and its metabolism by rat liver microsomes. Drug Metab. Dispos., 23: 1394-1399, 1995.
97. 6-benzylguanine in mice and dogs. Proc. Am. Assoc. Cancer Res., 35: 1953, 1994.
98. 6-benzylguanine. Biochem. Pharmacol., 50: 1385-1389, 1995.
99. 6-benzylguanine (BG) in patients with advanced cancer. Proc. Am. Assoc. Clin. Oncol., 15: 176, 1996.
100. 6-alkylguanine DNA alkyltransferase directed DNA repair. Proc. Am. Assoc. Clin. Oncol., 75: 177, 1996.
101. 6-benzylguanine. Cancer Res., 53: 4750-4753, 1993.
102. 6-benzylguanine. Cancer Res., 54: 6221-6227, 1994.
103. 6-methylguanine-DNA methyltransferase from E. coli. EMBO. J., 13: 1495-1501, 1994.
104. 6-benzylguanine and 2,4-diamino-6-benzyloxy-5-nitrosopyrimidine. Carcinogenesis (Lond.), 16: 1687-1692, 1995.
105. 6-alkylguanine-DNA alkyltransferase based on the crystal structure of the C-terminal domain of the Ada protein from Escherichia coli. Anti-Cancer Drug Design. 10: 75-95, 1995.
106. 6-benzylguanine. Cancer Res., 56: 5571-5575, 1996.
107. 6-methylguanine-DNA methyltransferase gene in young patients with adult type cancers and functional assay. Carcinogenesis (Lond.), 16: 2441-2445, 1995.
108. 6-benzylguanine to killing by N,N′-bis(2-chloroethyl)-N-nitrosourea. Cancer Res., 7: 1578-1583, 1996.
109. 6-Alkylguanine-DNA alkyltransferase activity in human myeloid cells. J. Clin. Invest., 76: 2106-2114, 1985.
110. 6-benzylguanine plus BCNU. Blood, 88: 1649-1655, 1996.
111. Devereux, S., Selassie, T. G., Hudson, G. V., Hudson, B. V., and Linch, D. C. Leukemia complicating treatment for Hodgkins disease: the experience of the British National Lymphoma Investigation. Br. Med. J., 301: 1077-1080, 1990.
112. Allay, J. A., Dumenco, L. L., Koc, O. N., Liu, L., and Gerson, S. L. Retroviral transduction and expression of the human alkyltransferase cDNA provides nitrosourea resistance to hematopoietic cells. Blood. 85: 3342-3351, 1995.
113. Harris, L. C., Marathi, U. K., Edwards, C. C., Houghton, P. J., Vanin, E. F., Sorrentino, B. P., and Brent, T. P. Retroviral transfer of a bacterial alkyltransferuse gene into murine bone marrow protects against nitrosourea cytotoxicity. Proc. Am. Assoc. Cancer Res., 36: 419, 1995.
114. Moritz, T., MacKay, W., Glassner, B. J., Williams, D. A., and Samson, L. Retrovirus-mediated expression of a DNA repair protein in bone marrow protects hematopoietic cells from nitrosourea-induced toxicity in vitro and in vivo. Cancer Res., 55: 2608-2614, 1995.
115. 6-alkylguanine-DNA alkyltransferase. Blood, 87: 1957-1961, 1996.
116. 6-methylguanine-DNA melhyltransferase gene into a murine hematopoietic stem cell line and resistance to the toxic effects of certain alkylating agents. Biochem. Pharmacol., 51: 1221-1228, 1996.
117. 6-benzylguanine plus BCNU. Proc. Natl. Acad. Sci. USA, in press, 1997.
118. 6-alkylguanine-DNA alkyltransferase. J. Med. Chem., 35: 4486-4491, 1992.
119. 6-alkylguanine-DNA alkyltransferase. J. Med. Chem., 37: 342-347, 1994.
120. 6-alkylguanine-DNA alkyltransferase. J. Med. Chem., 38: 359-365, 1995.
121. 6-substituted guanines). Anti-Cancer Drug Design, 9: 401-408, 1994.
122. 6-benzyl-N-acetylguanosine derivatives of chloroethylnitrosourea antitumor action in chloroethylnitrosourea-resistant human malignant melanocytes. J. Pharmacol. Exp. Ther., 271: 1353-1358, 1994.
123. 6-alkylguanine derivatives on chloroethylnitrosourea cytotoxicity toward tumor cells. Int. J. Cancer, 58: 706-712, 1994.
124. 6-alkylguanine-DNA alkyltransferase and N,N-bis(2-chloroethyl)-N-nitrosourea. Biochem. Pharmacol., 8: 1141-1148, 1995.
125. 6-Substituted guanine derivatives, a process for their preparation and their use in treating tumour cells. International patent application. WO94/29312, Dec. 22, 1994.
126. 6-benzyl-2′-deoxyguanosine and BCNU. Cancer Res., 56: 2076-2081, 1996.